Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sitagliptin Placebo Clear all
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

NCT00754988
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

NCT01035879
View directory record Official record
Conditions
Diabetes
Interventions
MBX-2982, Sitagliptin, placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Las Vegas, Nevada • Binghamton, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01951339
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
Sitagliptin, Glimepiride, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

NCT01177813
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Increased Incretin Hormone Exposure

NCT01374568
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
sitagliptin, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

NCT00871507
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ-38431055 Dose 1, Sitagliptin 100 mg, Placebo, JNJ-38431055 Dose 2
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Fort Myers, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 2, 2026, 6:50 AM EDT
Not listed Phase 4 Interventional

Bone Turnover in Type 2 Diabetes Patients

NCT00732121
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 27, 2010 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin for Reducing Inflammation and Immune Activation

NCT02513771
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Sitagliptin, Placebo for sitagliptin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT00901979
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LCQ908A, Placebo, Sitagliptin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
48
States / cities
Mesa, Arizona • Little Rock, Arkansas • Buena Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Incretins in Impaired Fasting Glucose

NCT00364377
View directory record Official record
Conditions
Pre-diabetes
Interventions
Sitagliptin, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930
View directory record Official record
Conditions
Obesity, PreDiabetes
Interventions
Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39)
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT03115112
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Lincoln, California • Long Beach, California • San Dimas, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

NCT02015910
View directory record Official record
Conditions
Type II Diabetes
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

NCT02363335
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Roflumilast/Sitagliptin, Sitagliptin, Roflumilast
Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

NCT00947011
View directory record Official record
Conditions
Glucose Homeostasis
Interventions
Placebo, Januvia
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed No phase listed Observational

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

NCT06914102
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
58,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant

NCT01186562
View directory record Official record
Conditions
Pancreatitis, Diabetes
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

Treatment of Diabetes After Gastric Bypass With Sitagliptin

NCT01512797
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin phosphate, Placebo
Drug · Other
Lead sponsor
Blandine Laferrere
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM

NCT00820573
View directory record Official record
Conditions
Diabetes
Interventions
Sitagliptin, Metformin, Sitagliptin + Metformin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 2, 2026, 6:50 AM EDT